Tuesday 16th April 2019 10:00 EST/ 15:00 GMT / 16:00 CEST
China has always been believed to be the land of promise for multinational pharmaceutical companies. However, up until recently many organisations have struggled to see a return on their investments. That may all be set to change though.
The country’s recent 2020 healthcare reforms aim to rapidly increase the pace of new drug approvals and fast track innovative treatments, opening up a whole new world of opportunities for the pharmaceutical industry.
Register now for our next live webinar in which emerging markets experts Marc Yates and Helen Ansell will explore China’s evolving healthcare environment, highlight the key changes affecting pharma and show you how to build the market understanding required to launch a brand effectively in this exciting region.
When: Tuesday 16th April 2019
Time: 10:00 EST/ 15:00 GMT / 16:00 CEST
Register now to secure your place »
China’s key growth factors:
Fast track approvals: So far, over 180 foreign pharma products have been granted priority review and will likely hit the market within the next few years.
From an ability to pay to willingness to pay: By 2022 more than half of the urban population will be defined as upper middle class and as incomes rise so does willingness to pay for quality healthcare.
Shifting disease patterns: Diseases of affluence are also on the rise and the benefits of urban life have resulted in an aging population and an explosion in age-related conditions.
What are the key takeaways in this webinar?
1. China 101
An overview of the healthcare environment in China
2. What’s changed?
The key opportunities under China’s 2020 healthcare reform
3. Where to play? How to win?
Design an effective marketing strategy with insights that prepare you for optimal success.
4. Gain answers to your key questions
Start the conversation by submitting your questions in advance when you register.
Register now to secure your place »
If you are unable to attend but would like to view the recording, register now and we will send you a unique link to download it as soon as it is ready.
This content was provided by Research Partnership
Company Details
Latest Content from Research Partnership
Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.
Marc Yates, Director of Emerging Markets at pharma market research specialist Research Partnership, shares insights from his experience of working in BRIC and beyond.
Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding.
Mary Assimakopoulos, Founding Director of global pharma market research specialist Research Partnership discusses how pharma can benefit from improved patient understanding
Oncology is arguably the most exciting area of medicine in which to be working today. Biomarkers and companion diagnostics offer incredibly valuable predictive power, which is of benefit to payers,...
A new study conducted by Research Partnership reveals that 90% of physicians treating HCV patients in the US have reported they are now “warehousing” patients (holding off treatment) in expectation...
Rheumatologists believe that the current market for biologic treatments in Rheumatoid Arthritis (RA) will see key changes in the next three years.
How can pharma benefit from improved patient understanding? Welcome to a new column in which Mary Assimakopoulos, Founding Director of pharma market research specialist the Research Partnership reveals findings from...
Following a survey of 1000 Psoriatic Arthritis patients, Mary Assimakopoulos shares some of the root causes behind a late diagnosis of this debilitating illness, and the patients’ own feelings towards...
This month Mary Assimakopoulos examines some of the insights gathered while surveying 2,000 patients suffering with this often misunderstood mental illness.